EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Nirmatrelvir–ritonavir versus usual care in at-risk adults with early SARS-CoV-2 infection in the UK, 2022–23: virological and immunological results of an open-label randomised trial (PANORAMIC)

David M Lowe, Shengyuan Zhang, Samuel Ellis, Laura Buggiotti, Charles Miller, Victoria Harris, Adrian M Shields, Alex G Richter, Elen Ashmore, Ly-Mee Yu, Saye Khoo, F D Richard Hobbs und 5 weitere

The Lancet Microbe · 2026

DOI: 10.1016/j.lanmic.2026.101360 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift The Lancet Microbe, 2026. Verfasst von David M Lowe und 16 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Immunity and Transplantation, University College London, London, UK; Department of Clinical Immunology, Royal Free London NHS Foundation…. Hauptthemen laut MEDLINE: Ritonavir, SARS-CoV-2, COVID-19 Drug Treatment, Antiviral Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council, National Institute for Health and Care Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Nirmatrelvir-ritonavir is widely used for COVID-19, but effectiveness was established in unvaccinated people with SARS-CoV-2 variants before omicron. Within the randomised Platform Adaptive Trial of Novel Antivirals for Early Treatment of COVID-19 in the Community (PANORAMIC) trial, we did a substudy to evaluate virological and immunological outcomes. METHODS: Adults (aged ≥50 years, or ≥18 years with comorbidities) with early COVID-19 were recruited across the UK in an open-label trial and randomly assigned to receive nirmatrelvir-ritonavir twice daily for 5 days plus usual care (nirmatrelvir-ritonavir group) or usual care alone (supportive treatment only with the use of antipyretics as required; usual care group). Before randomisation, participants were also invited to enter the virology substudy, and those who consented were sent swabs and blood spot testing kits for self-sampling with instructions. We performed viral quantitative PCR, viral culture, and sequencing on self-collected combined nasal and pharyngeal swabs submitted daily for 7 days and at day 14 (intensive sampling group) or at baseline, day 5, and day 14. We measured blood spot SARS-CoV-2 spike antibody titre and C-reactive protein (CRP) at baseline, day 5, and day 14 in all participants. We undertook mixed-effects modelling to identify predictors of viral load or spike antibody rate of change and assessed viral rebound by multiple definitions. The trial was registered with EudraCT, 2021-005748-31. FINDINGS: From Sept 10, 2022, to Oct 23, 2023, 649 people agreed to participate in the virology substudy, of whom 27 were excluded per the prespecified analysis plan, resulting in 622 participants in the analysis: 326 in the nirmatrelvir-ritonavir group and 296 in the usual care group. Nirmatrelvir-ritonavir treatment reduced viral load from day 5 onwards and increased viral clearance. The estimated half-life was 0·78 days (95% CI 0·74-0·83) with usual care versus 0·66 days (95% CI 0·56-0·68) with nirmatrelvir-ritonavir; p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RitonavirSARS-CoV-2COVID-19 Drug TreatmentAntiviral AgentsCOVID-19HumansMiddle AgedUnited KingdomFemaleMaleAgedViral LoadAntibodies, ViralTreatment Outcome

Substanzen

RitonavirAntiviral AgentsAntibodies, Viral

Autor:innen und Institutionen

  • Institute of Immunity and Transplantation, University College London, London, UK; Department of Clinical Immunology, Royal Free London NHS Foundation Trust, London, UK. Electronic address: d.lowe@ucl.ac.uk.
  • Infection, Immunity, and Inflammation, Great Ormond Street Institute of Child Health, University College London, London, UK.
  • Great Ormond Street Hospital for Children NHS Trust, London, UK.
  • Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
  • Clinical Immunology Services, School of Infection, Inflammation and Immunology, College of Medicine and Health, University of Birmingham, Birmingham, UK.
  • Department of Pharmacology, University of Liverpool, Liverpool, UK; Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK.

Förderung

  • Medical Research Council
  • National Institute for Health and Care Research

Zitieren

APA

Lowe, D. M., Zhang, S., Ellis, S., Buggiotti, L., Miller, C., Harris, V., Shields, A. M., Richter, A. G., Ashmore, E., Yu, L. M., Khoo, S., Hobbs, F. D. R., Little, P., Butler, C. C., Breuer, J., Standing, J. F., & PANORAMIC Trial Collaborative Group and PANORAMIC Trial Virology Group (2026). Nirmatrelvir–ritonavir versus usual care in at-risk adults with early SARS-CoV-2 infection in the UK, 2022–23: virological and immunological results of an open-label randomised trial (PANORAMIC). The Lancet Microbe. https://doi.org/10.1016/j.lanmic.2026.101360

Vancouver

Lowe DM, Zhang S, Ellis S, Buggiotti L, Miller C, Harris V, et al. Nirmatrelvir–ritonavir versus usual care in at-risk adults with early SARS-CoV-2 infection in the UK, 2022–23: virological and immunological results of an open-label randomised trial (PANORAMIC). The Lancet Microbe. 2026. doi:10.1016/j.lanmic.2026.101360

BibTeX
@article{Lowe2026,
  author = {Lowe, David M and Zhang, Shengyuan and Ellis, Samuel and Buggiotti, Laura and Miller, Charles and Harris, Victoria and Shields, Adrian M and Richter, Alex G and Ashmore, Elen and Yu, Ly-Mee and Khoo, Saye and Hobbs, F D Richard and Little, Paul and Butler, Christopher C and Breuer, Judith and Standing, Joseph F and PANORAMIC Trial Collaborative Group and PANORAMIC Trial Virology Group, PANORAMIC Trial Collaborative Group and PANORAMIC Trial Virology Group},
  title = {Nirmatrelvir–ritonavir versus usual care in at-risk adults with early SARS-CoV-2 infection in the UK, 2022–23: virological and immunological results of an open-label randomised trial (PANORAMIC)},
  journal = {The Lancet Microbe},
  year = {2026},
  doi = {10.1016/j.lanmic.2026.101360}
}
Kostenlos starten →